心脏骤停后综合征患者应用CRRT清除谷氨酸72小时:一项随机临床先导试验
该前瞻性随机临床先导试验纳入41例心脏骤停后生存者,随机分为标准治疗组(n=21)和标准治疗加72小时CVVHDF组(n=20),在8个时间点检测血浆谷氨酰胺和谷氨酸浓度。主要终点即CVVHDF降低谷氨酰胺和谷氨酸血浆浓度未达成,两组浓度在整个研究期间均维持在正常范围(谷氨酸:4.7-11.1 mg/dL;谷氨酰胺:0.2-3.7 mg/dL)。然而,CRRT患者滤器后谷氨酰胺和谷氨酸浓度较滤器前显著降低(谷氨酸:滤器前中位数8.85 mg/dL,IQR 7.1-9.6;滤器后0.95 mg/dL,IQR 0.5-2;p<0.001;谷氨酰胺:滤器前0.7 mg/dL,IQR 0.6-1;滤器后0.2 mg/dL,IQR 0-0.2;p<0.001)。作者结论认为CVVHDF未能统计学显著降低全身血浆谷氨酰胺和谷氨酸水平,心脏骤停后患者血浆谷氨酰胺和谷氨酸水平在正常范围内。
要点
- 心脏骤停后综合征患者血浆谷氨酸(4.7-11.1 mg/dL)和谷氨酰胺(0.2-3.7 mg/dL)水平在正常范围内。
- CVVHDF 72小时未能统计学显著降低全身血浆谷氨酰胺和谷氨酸浓度,主要终点未达成。
- CVVHDF组滤器后谷氨酸浓度较滤器前显著降低(滤器前中位数8.85 mg/dL vs 滤器后0.95 mg/dL,p<0.001)。
- CVVHDF组滤器后谷氨酰胺浓度较滤器前显著降低(滤器前0.7 mg/dL vs 滤器后0.2 mg/dL,p<0.001)。
- 该试验为随机临床先导试验,共纳入41例患者(对照组21例,CVVHDF组20例)。
适用人群与场景
- 心脏骤停后生存者(post-cardiac arrest survivors),入住后立即开始研究干预。
处置流程与药物剂量
- 标准治疗或标准治疗加连续静脉-静脉血液透析滤过(CVVHDF)72小时,自入住后立即开始。
研究设计与关键结果
- 前瞻性随机临床先导试验,共随机41例患者(对照组n=21,CVVHDF组n=20),研究期12个月。
- 主要终点即CVVHDF降低谷氨酰胺和谷氨酸血浆浓度未达成;两组浓度均维持在正常范围(谷氨酸:4.7-11.1 mg/dL;谷氨酰胺:0.2-3.7 mg/dL)。
- CRRT患者滤器后谷氨酸浓度较滤器前显著降低:滤器前中位数8.85 mg/dL(IQR 7.1-9.6)vs 滤器后0.95 mg/dL(IQR 0.5-2),p<0.001。
- CRRT患者滤器后谷氨酰胺浓度较滤器前显著降低:滤器前0.7 mg/dL(IQR 0.6-1)vs 滤器后0.2 mg/dL(IQR 0-0.2),p<0.001。
证据类型、等级与局限
- 证据类型:前瞻性随机临床先导试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为CVVHDF未能统计学显著降低全身血浆谷氨酰胺和谷氨酸水平,心脏骤停后患者血浆谷氨酰胺和谷氨酸水平在正常范围内。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: Glutamine and glutamate are major mediators of secondary brain cell death during post-cardiac arrest syndrome. As there is an equilibrium between brain tissue and plasma concentrations of glutamine and glutamate, their elimination from systemic circulation by extracorporeal blood purification may ultimately lead to reduced secondary cell death in the brain. We hypothesized that systemic glutamine and glutamate can be significantly reduced by continuous venovenous hemodiafiltration (CVVHDF).
METHODS: This was a prospective, randomized clinical trial in post cardiac-arrest survivors evaluating standard of care or additional CVVHDF over 72 h immediately after admission. Glutamine and glutamate plasma concentrations were analyzed at eight time points in both groups. Primary endpoint was reduction of glutamine and glutamate plasma concentrations. The trial has been registered at clinical trial.gov (NCT02963298).
RESULTS: In total, 41 patients were randomized over a period of 12 months (control n = 21, CVVHDF n = 20). The primary aim reduction of glutamine and glutamate plasma concentrations by CVVHDF, was not achieved; both groups-maintained concentrations within a normal range over the study period (glutamate: 4.7-11.1 mg/dL; glutamine: 0.2-3.7 mg/dL). However, post-filter concentrations of glutamine and glutamate in CRRT patients were significantly decreased as compared to pre-filter concentrations (glutamate: pre-filter median 8.85 mg/dL IQR 7.1-9.6; post-filter 0.95 mg/dL IQR 0.5-2; p < 0.001; glutamine: pre-filter 0.7 mg/dL IQR 0.6-1; post-filter 0.2 mg/dL IQR 0-0.2; p < 0.001).
CONCLUSION: In this trial, CVVHDF was not able to statistically significantly lower systemic plasma glutamine and glutamate levels. Post-cardiac arrest patients had plasma glutamine and glutamate levels within the normal range.
参考来源
- Nee J, Jörres A, Krannich A, et al. Elimination of glutamate using CRRT for 72 h in patients with post-cardiac arrest syndrome: A randomized clinical pilot trial. Resuscitation. 2019. PMID: 31557520. doi:10.1016/j.resuscitation.2019.09.020
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。